Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis

Dermatol. Ther.

Patients with moderate-to-severe psoriasis (PsO) overwhelmingly remained on ixekizumab treatment for more than 2 years while participating in a PSP.